This is a rough week for Halozyme Therapeutics (NASDAQ:HALO). The company’s rating falls to D from the previous week’s C. Halozyme Therapeutics is a biopharmaceutical company developing products for the diabetes, cancer, dermatology and drug delivery markets. The stock receives F’s in Earnings Growth, Earnings Momentum, Equity, and Sales Growth. Wall Street appears to agree with the stock downgrade, with share prices dropping 29.5% over the past month. To get an in-depth look at HALO, get Portfolio Grader’s complete analysis of HALO stock.